<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1349">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393805</url>
  </required_header>
  <id_info>
    <org_study_id>HETHICO</org_study_id>
    <nct_id>NCT04393805</nct_id>
  </id_info>
  <brief_title>Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto</brief_title>
  <acronym>HETHICO</acronym>
  <official_title>Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quovadis Associazione</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Quovadis Associazione</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HETHICO study aims to collect retrospectively documented clinical information on patients
      hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings,
      medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the
      safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or
      in preventing thrombotic complications related to hospitalization from COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HETHICO study aims to collect retrospectively documented clinical information on patients
      hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings,
      medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the
      safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or
      in preventing thrombotic complications related to hospitalization from COVID-19.

      Furthermore, the possible association between the observed clinical evolution and the type of
      antithrombotic prophylaxis performed (class of drug and dose intensity) will be assessed in a
      large cohort of patients hospitalized in the various participating hospitals in the Veneto
      region and observed with follow-up. in the short term, gathering information on:

      Clinical outcomes, Survival, Concomitant pathologies, Adverse events of anticoagulant drugs,
      Interactions with other concomitant drugs, and Risk factors.

      The collected data, suitably anonymized, will be used to produce scientific works, the
      standardization of care paths, and the planning of targeted training events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>Collect and evaluate in real-life the safety data of the anti-coagulant treatments used by estimating the incidence of bleeding complications during hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thrombosis</measure>
    <time_frame>28 days</time_frame>
    <description>Collect and evaluate in real-life the efficacy data of the anti-coagulant treatments used by estimating the incidence of deep vein thrombosis and/or pulmonary embolism during hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Collect and evaluate in real-life the data by estimating incidence of intra-hospital death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Worsening</measure>
    <time_frame>28 days</time_frame>
    <description>clinical worsening with transfer to the intensive/sub-intensive ward</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LOS</measure>
    <time_frame>60 days</time_frame>
    <description>length of stay</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">877</enrollment>
  <condition>COVID-19</condition>
  <condition>Hypercoagulability</condition>
  <arm_group>
    <arm_group_label>MED-Cohort</arm_group_label>
    <description>Patients hospitalized for SARS-COVID-2 infection in a medical ward</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ICU-Cohort</arm_group_label>
    <description>Patients hospitalized for SARS-COVID-2 infection in a sub-intensive or intensive care unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Molecular Weight Heparin</intervention_name>
    <description>Thromboprophylaxis with Low Molecular Weight Heparin, mostly enoxaparin</description>
    <arm_group_label>ICU-Cohort</arm_group_label>
    <arm_group_label>MED-Cohort</arm_group_label>
    <other_name>LMWH</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects of both sexes, aged 18 years or older (no maximum age of inclusion) will be
        eligible for this study, who have been hospitalized in the participating Operating Units
        (Centers) of Veneto Region Hospitals with infection SARS-COVID-2.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  proved SARS-COVID-2 infection

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Simioni, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, University of Padua (I)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paolo Simioni, Prof.</last_name>
    <phone>+39 0498212667</phone>
    <email>paolo.simioni@unipd.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Giuseppe Camporese</name>
      <address>
        <city>Padova</city>
        <zip>35138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe MD Camporese</last_name>
      <phone>‭+39 049 8212933‬</phone>
      <email>giuseppe.camporese@aopd.veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 pandemic</keyword>
  <keyword>Hypercoagulability state</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

